Clinical trialNCT00689611CompletedPhase 3Interventional

Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial

SponsorMark EisenbergEnrollment392Acute Coronary SyndromeMyocardial InfarctionSmoking

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%. A variety of smoking cessation aids have been shown to be effective for the general population. However, bupropion is the only non-nicotine replacement therapy shown to improve abstinence rates in healthy young smokers. Furthermore, nicotine replacement therapies (NRTs) are contraindicated in the immediate period following a heart attack because of the undesirable effects of nicotine. Although bupropion has been successfully used to reduce smoking rates in healthy young populations, its efficacy and safety in the setting of patients recovering from an ACS is unknown. These patients, if they continue to smoke, are at exceptionally high risk for recurrent cardiac events. If bupropion is effective in this population, it will have a major impact on secondary prevention of recurrent clinical events in patients who suffer a heart attack.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Mark J Eisenberg, MD, MPH
Jewish General Hospital/ McGill University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Bangladesh

National Heart Foundation of Bangladesh
Dhaka, Bangladesh

Canada

Peter Lougheed Centre of the Calgary General Hospital
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Vancouver Coastal Health
Vancouver, British Columbia, Canada
St. Boniface General Hospital
Winnipeg, Manitoba, Canada
Victoria General Hospital
Winnipeg, Manitoba, Canada
New Brunswick Heart Centre
Saint Johns, New Brunswick, Canada
Valley Regional Hospital
Kentville, Nova Scotia, Canada
the Ottawa Hospital, General Campus
Ottawa, Ontario, Canada
St. Michael'S Hospital
Toronto, Ontario, Canada
Hopital de la Cite de la Sante
Laval, Quebec, Canada
Cha Hotel-Dieu de Levis
Lévis, Quebec, Canada
Hopital Sacre-Coeur de Montreal
Montreal, Quebec, Canada
Hotel-Dieu
Montreal, Quebec, Canada
Montreal General Hospital
Montreal, Quebec, Canada
Smbd- Jewish General Hospital
Montreal, Quebec, Canada
Hopital Laval
Québec, Quebec, Canada
Hopital Fleurimont
Sherbrooke, Quebec, Canada
Csss de Sorel-Tracy
Sorel-Tracy, Quebec, Canada
Csss de la Region de Thetford
Thetford-Mines, Quebec, Canada
Saskatchewan Drug Research Institute
Saskatoon, Saskatchewan, Canada

India

Centre for Chronic Disease Control
New Delhi, India

Iran

Isfahan Cardiovascular Research Centre
Isfahan, Iran, Iran

Pakistan

Interactive Research and Development
Karachi, Pakistan

Tunisia

University Hospital F. Bourguiba
Sousse, Sousse Governorate, Tunisia

United States

Parkview Medcial Center
Pueblo, Colorado, United States
Central Maine Medical Center
Lewiston, Maine, United States
Bay Regional Medical Center
Bay City, Michigan, United States
Bassett Healthcare
Cooperstown, New York, United States
United Health Services
Johnson City, New York, United States
Stony Brook Hospital and Medical Center
Stony Brook, New York, United States
Schuster Cardiology
Kettering, Ohio, United States
Southwest Cardiology
Kettering, Ohio, United States
Dva Medical Center
Oklahoma City, Oklahoma, United States
Advanced Cardiology Specialists
Scranton, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Riverside Hospital
Newport News, Virginia, United States
Charleston Area Medical Center
South Charleston, West Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bupropion HCl ERPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2005
Primary completion: 30 Jun 2010
Completion: 30 Jun 2010
Last update posted: 23 Apr 2015
Registered enrollment: 392
Registry id: NCT00689611

Cross-registrations

ISRCTN (UK)ISRCTN75356261

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.